Imaging the inflammatory activity of sarcoidosis: Sensitivity and inter observer agreement of 67Ga imaging and 18F-FDG PET

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 1, 2011, Pages 66-71

  Keijsers, R G ^a   Grutters, J C ^a   Thomeer, M ^b   Du Bois, R M ^c   Van Buul, M M ^a   Lavalaye, J ^a   Van Den Bosch, J M ^a   Verzijlbergen, F J ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Diagnostic imaging; Fluodeoxyglucose F18; Position emission tomography; Sarcoidosis

Indexed keywords

COVIDIEN; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INFLAMMATION; LUNG SARCOIDOSIS; LYMPH NODE; MALE; MEDIASTINUM; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SARCOIDOSIS; SARCOIDOSIS, PULMONARY; SENSITIVITY AND SPECIFICITY;

EID: 79957451426     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994;7:624-7.
2. Kohn H, Klech H, Mostbeck A, Kummer F. 67Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. Eur J Nucl Med 1982;7:413-6. (Pubitemid 12015194)
3. Johnson DG, Johnson SM, Harris CC, Piantadosi CA, Blinder RA, Coleman RE. Ga-67 uptake in the lung in sarcoidosis. Radiology 1984;150:551-5. (Pubitemid 14224595)
4. Braun JJ, Kessler R, Constantinesco A, Imperiale A. (18)F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008;35:1537-43.
5. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.
6. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132:1949-53.
7. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998;39:1160-6. (Pubitemid 28326144)
8. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571-6. (Pubitemid 47545019)
9. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
10. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-33.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
12. Zijlstra JM, Hoekstra OS, Raijmakers PG, Comans EF, van der Hoeven JJ, Teule GJ et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003;123:454-62.
13. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998;28:1-126.